Core Viewpoint - 泰德医药 is positioned as the third largest global player in the peptide-focused CRDMO market, with a market share of 1.5% as of 2023, according to the Hong Kong Stock Exchange and Frost & Sullivan data [1][3]. Company Overview - 泰德医药 offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production, primarily focusing on CRO and CDMO services related to peptide NCE discovery and CMC development [3][4]. - The company has established stable customer relationships in over 50 countries, including major markets such as China, the US, Japan, Europe, South Korea, and Australia [3]. Market Position - The global peptide CRDMO market is dominated by two major players holding 23.8% of the market share, while the remaining participants, including 泰德医药, hold approximately 1% each [3]. - The global peptide drug market has grown from $60.7 billion in 2018 to $89.5 billion in 2023, with a compound annual growth rate (CAGR) of 8.1%, and is projected to reach $261.2 billion by 2032, with a CAGR of 12.6% [4]. Project Pipeline - As of December 31, 2024, 泰德医药 has a project pipeline consisting of 1,217 ongoing CRO projects and 332 ongoing CDMO projects, with a strategic focus on GLP-1 related projects [4]. Financial Performance - For the fiscal years 2022, 2023, and 2024, 泰德医药 reported revenues of approximately RMB 351 million, RMB 337 million, and RMB 442 million, respectively, with net profits of approximately RMB 54 million, RMB 49 million, and RMB 59 million [6].

Core Insights - The report highlights a positive outlook for various sectors, with specific companies identified as key investment opportunities based on their performance and market conditions [5][11][15][19][23][27][31][35][39][44]. Company Summaries 招商银行 (China Merchants Bank, 600036) - The bank's Q1 2025 performance showed a decline in revenue and net profit, with operating income at 837.51 billion yuan, down 3.09% year-on-year, and net profit at 372.86 billion yuan, down 2.08% [11]. - The bank maintains a high dividend payout ratio, with a projected dividend of 2 yuan per share for 2024, resulting in a dividend yield of 4.60% based on the May 29 closing price [11]. - The bank's asset quality remains under pressure, particularly in retail loans, with a non-performing loan ratio of 0.94% [11]. 紫金矿业 (Zijin Mining, 601899) - The company reported significant growth in mineral production, achieving 1.07 million tons of copper and 73 tons of gold in 2024, with production costs decreasing [15]. - Zijin Mining's resource reserves are expanding, with successful exploration projects and acquisitions enhancing its market position [15]. - The company expects continued growth in copper and gold prices, supporting its revenue projections for 2025 [15]. 三美股份 (Sanmei Co., 603379) - The company experienced a substantial increase in revenue from its refrigerant products, with a 30.28% year-on-year growth in 2024 [19]. - The average selling price of refrigerants rose significantly, contributing to improved profitability [19]. - The company is well-positioned in the refrigerant market, with ongoing price increases expected in 2025 [19]. 青岛啤酒 (Qingdao Beer, 600600) - The company reported a revenue of 321.38 billion yuan in 2024, with a net profit of 43.45 billion yuan, showing signs of recovery in the beverage sector [23]. - The management is optimistic about demand recovery as the peak season approaches, supported by favorable government policies [23]. - EPS projections for 2025 are set at 3.52 yuan, with a "buy" rating maintained [23]. 恒瑞医药 (Hengrui Medicine, 600276) - The company achieved a 20.14% year-on-year growth in revenue for Q1 2025, driven by its innovative drug portfolio [27]. - Hengrui's focus on R&D has led to the development of multiple new drugs, enhancing its market competitiveness [27]. - EPS for 2025 is projected at 1.05 yuan, with a "buy" rating maintained [27]. 海大集团 (Haida Group, 002311) - The company reported a 9% increase in feed sales in 2024, with significant growth in international markets [31]. - Haida is actively pursuing international expansion, particularly in Southeast Asia and Africa, to enhance its market presence [31]. - EPS projections for 2025 are set at 3.01 yuan, with a "buy" rating maintained [31]. 华电国际 (China Huadian Corporation, 600027) - The company completed a significant asset restructuring, expected to enhance its operational scale and market share [35]. - Post-restructuring, the company anticipates a 25.07% increase in revenue and a 5.93% increase in net profit [35]. - EPS projections for 2025 are set at 0.64 yuan, with a "buy" rating maintained [35]. 胜宏科技 (Shenghong Technology, 300476) - The company reported a 35.31% increase in revenue for 2024, driven by strong demand in the PCB sector [39]. - Q1 2025 saw an 80.31% increase in revenue, with significant growth in high-value product orders [39]. - EPS projections for 2025 are set at 5.09 yuan, with a "buy" rating maintained [39]. 中国电信 (China Telecom, 601728) - The company reported a 3.1% year-on-year increase in revenue, with a focus on digital transformation and service innovation [44]. - The mobile user base continues to grow, contributing to stable revenue streams [44]. - EPS projections for 2025 are set at 0.39 yuan, with a "buy" rating maintained [44].

Investment Strategy - The report suggests gradually increasing risk appetite for thematic trading as June approaches, noting that thematic trading often performs well in June, with high market attention on sectors like innovative pharmaceuticals and IP economy [2][8] - The trading strategy is shifting from focusing on individual stocks with unexpected performance to high-growth industries, recommending attention to sectors such as feed, motorcycles, plastics, animal health, and batteries [2][8] June Stock Recommendations 1. **Yinlong Co., Ltd. (603969.SH)**: Expected to achieve over 30% compound annual growth in profits over the next 2-3 years due to the high-end trend in prestressed materials and strong order visibility [9][10] 2. **Cambricon Technologies (688256.SH)**: Anticipated to enter a profit explosion phase, with significant increases in inventory and cash flow indicating strong demand for main chips [11][12] 3. **Yanjing Beer (000729.SH)**: The main product U8 is expected to maintain over 30% growth, supported by seasonal demand and improved market conditions [17][18] 4. **Xintian Green Energy (600956.SH)**: Projected revenue growth driven by stable wind power generation and ongoing expansion in natural gas operations [19][20] 5. **Huaneng International (600011.SH)**: Expected profit growth due to reduced fuel costs and ongoing expansion in renewable energy capacity [23][24] 6. **Salted Fish (002847.SZ)**: Anticipated revenue growth from successful product launches in the konjac category and effective channel expansion strategies [14][15]

策略早餐 主要品种策略早餐 （2025.06.03） 养殖、畜牧及软商品板块 品种：生猪 核心逻辑： 1、供应方面，截至 2025 年 4 月，据农业农村部数据，全国能繁母猪存栏量为 4038 万头，环比持平，同比增长 1.3%。这一数据反映出自 2024 年 4 月以来，产能 累计上升 1.3%，处于较为平稳的格局，暂未出现产能下滑的情况。而根据第三方机 构钢联数据及涌益咨询的数据显示，2025 年 4 月能繁母猪存栏量环比小幅上升，尽 管第三方机构与官方数据在统计口径上存在一定的差异，但环比上涨在一定程度上 体现了市场上暂无去产能的驱动，甚至部分企业开始缓慢恢复产能。5 月份看来， 生猪市场情绪支撑因素仍存，叠加仔猪价格暂未明显下跌，预计上有能繁母猪存栏 量或仍然稳中有增。根据产能数据推算的生猪供应量仍然充足，暂未看到供应量下 降的格局。 2、需求方面，从投机性需求来看，据钢联数据统计，5 月 23 日当周国内重点 屠宰企业的冻品库容率为 17.28%，与上一周持平，处于历史低位。当前由于需求表 现疲软，冻品市场需求暂未改善，出库维持缓慢节奏。而部分屠宰企业现品销售困 难，存在被动分割入库的情况，综合导致 ...

Core Points - The Annual General Meeting (AGM) of Afarak Group SE was held on June 3, 2025, in Helsinki, where the financial statements for 2024 were adopted and the Board of Directors and CEO were discharged from liability [1] - The AGM resolved that no dividend would be paid for 2024, but authorized the Board to distribute a maximum of EUR 0.005 per share from retained earnings or assets from the reserve for invested unrestricted equity, valid until December 31, 2025 [2] - The Board of Directors will consist of three members, with Dr. Jelena Manojlovic and Mr. Thorstein Abrahamsen re-elected, and Mr. Julien Duniague elected as a new member [3] - Non-executive Board Members will receive EUR 5,000 per month, with the Chairman receiving an additional EUR 1,500, and committee members receiving an extra EUR 1,500 for their work [4] - Tietotili Audit Oy was re-elected as the auditor of the Company, with Urpo Salo as the principal responsible auditor [5] - Tietotili Audit Oy was also elected as the sustainability reporting assurer, with Urpo Salo responsible for sustainability reporting [6] - Following the AGM, Mr. Thorstein Abrahamsen was re-elected as Chairperson of the Board, with specific committee compositions outlined [7] - The Company has a total of 277,041,814 shares, holding 15,641,514 shares in treasury as of June 3, 2025 [8] - Afarak Group specializes in alloy production, focusing on sustainable growth in its Specialty Alloys business in southern Europe and FerroAlloys business in South Africa, and is listed on NASDAQ Helsinki and the London Stock Exchange [10]

Group 1 - Dazhu CNC has submitted an IPO application to the Hong Kong Stock Exchange, positioning itself as a leading provider of PCB production equipment solutions [1] - According to the prospectus, Dazhu CNC is the largest manufacturer of PCB-specific production equipment globally, with a market share of 6.5% based on projected 2024 revenue [1] - Financial data indicates that Dazhu CNC's revenues for 2022, 2023, and 2024 are projected to be 2.786 billion, 1.634 billion, and 3.343 billion respectively, with net profits of 432 million, 148 million, and 452 million [1] Group 2 - Tongguan Copper Foil has successfully exported its electronic circuit copper foil products to Malaysia, expanding its international market presence [2] - The company has achieved a significant milestone with its HVLP series copper foil sales surpassing 1,000 tons, indicating strong market competitiveness [4] - In the first four months of 2025, sales of the HVLP series have already exceeded the total sales for the entire year of 2024, demonstrating continuous growth [4]

Core Viewpoint - The stock price of Ruizhi Pharmaceutical (300149.SZ) surged significantly before the Dragon Boat Festival, drawing attention from the capital market due to a combination of favorable news and improved financial performance [1][2][3]. Company Summary - Ruizhi Pharmaceutical's stock experienced a consecutive two-day "20cm" limit up on May 29 and 30, resulting in a cumulative increase of 44% [2]. - The company has seen a turnaround in its financial performance, achieving a net profit for the first quarter of 2025 after two years of substantial losses, with a reported net profit of 6.64 million yuan, a significant recovery compared to previous losses [3][8]. - The company has eliminated its goodwill burden, which had previously impacted profitability, and reported a revenue of 261 million yuan for Q1 2025, reflecting an 11.4% year-on-year increase [8]. - Ruizhi Pharmaceutical specializes in the CXO (Contract Research Organization) sector, providing comprehensive services from drug discovery to commercial production for global biopharmaceutical clients [4]. Industry Summary - The Chinese pharmaceutical industry is experiencing a "approval wave" for new drugs, which has acted as a catalyst for the current market rally [3]. - The global biopharmaceutical investment and financing environment is showing signs of recovery, with a projected increase from 71 billion USD in 2023 to 102 billion USD in 2024, marking a 43.7% year-on-year growth [8]. - The recent approval of 11 new drugs by the National Medical Products Administration of China has broadened the scope of innovative drug development, covering various therapeutic areas including oncology and autoimmune diseases [4].

如今，不少食品外包装上多了一个拇指大小的二维码，用手机扫描就可以看到食品的配料表、生产日期 等信息。这个二维码是我国正在推广的食品数字标签。近日发布的《食品安全国家标准预包装食品标签 通则》（GB 7718—2025），首次将数字标签纳入食品标签标准体系。 民以食为天，食以安为先。数字标签为食品企业提供透明化展示窗口，需要企业具备较强的数字能力， 确保食品的生产、运输和经营等环节符合数字标签的标准要求。由于不同企业的数字化水平存在差异， 转变并非一蹴而就，而是一个渐进的过程，需要在政府机构的指导和行业协会的引领下，以行业内的数 字化标杆企业为典范，逐步探索和实施数字化转型。 （文章来源：经济日报） 数字标签是食品标签的一部分，企业在推广应用数字标签时，必须始终将合规性放在首位。应注意其内 容必须符合食品安全法、广告法、消费者权益保护法和《食品安全国家标准预包装食品标签通则》 （GB 7718—2025）等相关法律法规的要求，确保数字标签内容的真实性、准确性，不能误导消费者， 确保"码上信息"真实可信，以增进消费者信任，维护企业声誉。 此外，包装上的字太小，配料表密密麻麻看不清，曾是许多老年消费者选购食品时的共 ...

打假。 国家能源集团网站6月1日消息，国家能源集团发布《关于不法分子假冒国家能源集团设立"拓展中心"进行违法活动的严正声明》。 近期，国家能源集团发现有不法分子假冒国家能源集团在全国多地设立所谓"拓展中心"，涉嫌从事违法活动，并通过抖音、微信视频号等网络平台进行虚假宣传。 国家能源集团严正声明，国家能源集团从未在全国任何地区设立任何"拓展中心"或"拓展服务中心"等机构，从未向社会公众开展任何形式的"投资理财"或"股权认 购"等活动，从未开发或授权他人开发任何投资理财类手机APP；不法分子使用国家能源集团名号和商标的行为未经任何授权，其成立的"拓展中心"或"拓展服务中 心"等机构、其发布的一切投资理财产品及信息均与国家能源集团无关。国家能源集团已就有关情况向相关部门举报。请社会公众提高警惕，注意防范风险。 据介绍，国家能源投资集团有限责任公司（简称"国家能源集团"）于2017年11月28日正式挂牌，是经党中央、国务院批准，由中国国电集团公司和神华集团有限责 任公司联合重组成立的中央骨干能源企业，是国有资本投资公司改革、创建世界一流示范企业、国有企业公司治理示范的试点企业，2024年世界500强排名第84 位。 ...

5 . 2 4 - 5 . 3 0 周度研究成果 2 0 2 5 申 万 宏 源 宏 观 研 究 团 队 目录 深度专题 1、深度专题 | 如何看待美国法院裁定特朗普关税违法？——关税"压力测试"系列之十 热点思考 高频跟踪 电话会议 1、 "周见"系列会议第32期 《再谈"股债汇三杀" 》 2、 "洞见"系列会议第63期 热点思考 《中国制造"难替代性"？——"反脆弱"系列专题之八》 深度专题 1、 热点思考 | 美债"风暴"将至？——关税"压力测试"系列之九 2、热点思考 | 就业"新趋势"？ 3、热点思考 | 财政"前置"后该关注什么？ 1、 利润修复的持续性？——4月工业企业效益数据点评 2、国内高频 | 汽车销量持续走强 3、政策高频 | 众议院通过减税法案，市场再现"股债汇"三杀 4、政策高频 | 制造业是国民经济的重要支柱 5、Top Charts | 消费困局的"盲点"？——见微知著系列专题之六 深度专题 | 如何看待美国法院裁定特朗普关税违法？——关税"压力测试"系列之十 点击看全 文 深度专题 2025.5.29 大类资产&海外事件&数据：众议院通过减税法案，市场再现"股债汇Q"三杀 | ...